SCHEMBL3018140

SCHEMBL3018140

CC(C)(C)c1ccc(S(=O)(=O)C2CCN(c3nc(Cc4ccc(Cl)c(F)c4)cs3)CC2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PROKR1 Q8TCW9 3/20 0.34
FPR2 P25090 2/20 0.34
HTR2A P28223 2/20 0.34
HTR2C P28335 2/20 0.34
KCNH2 Q12809 2/20 0.34
DRD2 P14416 1/20 0.34
HSD11B1 P28845 4/20 0.33
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MOGAT2 Q3SYC2 3/20 0.33
NAMPT P43490 2/20 0.33
HRH3 Q9Y5N1 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
EPHX2 P34913 1/20 0.32
CTSS P25774 1/20 0.31
TP53 P04637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015929 0.93 TRPV1 (0.36) HTR2AHTR2CKCNH2DRD2HSD11B1
SCHEMBL3009616 0.92 CACNA1G (0.35) HTR2AHTR2CKCNH2DRD2HSD11B1
SCHEMBL3014922 0.92 LMNA (0.37) HSD11B1ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL3016901 0.91 GBA1 (0.39) PROKR1FPR2HTR2AHTR2CKCNH2
SCHEMBL3007239 0.90 HTR2A (0.40) PROKR1FPR2HTR2AHTR2CKCNH2
SCHEMBL3011420 0.90 HTR2A (0.42) PROKR1FPR2HTR2AHTR2CKCNH2
SCHEMBL3010530 0.89 HTR2A (0.35) PROKR1FPR2HTR2AHTR2CKCNH2
SCHEMBL3017935 0.89 HTR2A (0.35) PROKR1FPR2HTR2AHTR2CKCNH2
SCHEMBL3014833 0.89 L3MBTL1 (0.35) PROKR1FPR2HTR2AHTR2CKCNH2
SCHEMBL3004485 0.88 HTR2A (0.36) PROKR1FPR2HTR2AHTR2CKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA PROKR1 2080/4885FPR2 3310/4885HTR2A 752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.